Literature DB >> 17538006

Structurally unique inhibitors of human mitogen-activated protein kinase phosphatase-1 identified in a pyrrole carboxamide library.

John S Lazo1, John J Skoko, Stefan Werner, Branko Mitasev, Ahmet Bakan, Fumito Koizumi, Archibong Yellow-Duke, Ivet Bahar, Kay M Brummond.   

Abstract

Mitogen-activated protein kinase phosphatase 1 (MKP-1) is a tyrosine phosphatase superfamily member that dephosphorylates and inactivates cardinal mitogen-activated protein kinase (MAPK) substrates, such as p38, c-Jun NH(2)-terminal kinase, and extracellular signal-regulated kinase. Although these MAPK substrates regulate many essential cellular processes associated with human diseases, few pharmacological inhibitors have been described. The lack of readily available selective MKP-1 inhibitors has severely limited interrogation of its biological role and was one rationale for using a recently described tricyclic pyrrole-2-carboxamide library in our screening efforts. In this report we demonstrate the pharmacological richness of the pyrrole carboxamide library by the finding that 10 of 172 members inhibited human MKP-1. Two of the pyrrole carboxamides, PSI2106 and MDF2085, were especially notable in vitro inhibitors of recombinant human MKP-1 enzyme activity with IC(50) values of 8.0 +/- 0.9 and 8.3 +/- 0.8 microM, respectively. Both showed some selectivity for MKP-1 over the closely related phosphatases MKP-3, Cdc25B, VHR, and PTP1B. Computational examination of the surface properties near the catalytic site revealed that the phosphatases studied differ significantly in their electrostatic potential at the substrate binding site. The compounds inhibited MKP-1 reversibly but displayed mixed kinetics. Phosphatase inhibition was retained in the presence of physiologically relevant concentrations of glutathione. Molecular docking studies suggested that PSI2106 may interact with His(229) and Phe(299) on MKP-1. These results reveal the power of using a small focused library for identifying pharmacological probes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17538006     DOI: 10.1124/jpet.107.122242

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Mitogen-activated protein kinase phosphatase 1 (MKP-1) in macrophage biology and cardiovascular disease. A redox-regulated master controller of monocyte function and macrophage phenotype.

Authors:  Hong Seok Kim; Reto Asmis
Journal:  Free Radic Biol Med       Date:  2017-03-19       Impact factor: 7.376

Review 2.  Small molecule tools for functional interrogation of protein tyrosine phosphatases.

Authors:  Rongjun He; Li-Fan Zeng; Yantao He; Sheng Zhang; Zhong-Yin Zhang
Journal:  FEBS J       Date:  2012-08-16       Impact factor: 5.542

3.  Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.

Authors:  Suman Kundu; Keke Fan; Mingli Cao; Daniel J Lindner; Ralph Tuthill; Lili Liu; Stanton Gerson; Ernest Borden; Taolin Yi
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

Review 4.  Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease.

Authors:  Lyn M Wancket; W Joshua Frazier; Yusen Liu
Journal:  Life Sci       Date:  2011-12-13       Impact factor: 5.037

Review 5.  Mitogen activated protein kinase phosphatases and cancer.

Authors:  Kelly K Haagenson; Gen Sheng Wu
Journal:  Cancer Biol Ther       Date:  2010-03-17       Impact factor: 4.742

Review 6.  The role and target potential of protein tyrosine phosphatases in cancer.

Authors:  Taolin Yi; Daniel Lindner
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

Review 7.  Regulatory Roles of MAPK Phosphatases in Cancer.

Authors:  Heng Boon Low; Yongliang Zhang
Journal:  Immune Netw       Date:  2016-04-28       Impact factor: 6.303

Review 8.  Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening.

Authors:  Ahmet Bakan; John S Lazo; Peter Wipf; Kay M Brummond; Ivet Bahar
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation.

Authors:  Edgar Alfonso Romero-Sandoval; Ryan Horvath; Russell P Landry; Joyce A DeLeo
Journal:  Mol Pain       Date:  2009-05-28       Impact factor: 3.395

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.